PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1401871
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1401871
According to Stratistics MRC, the Global RNA Sequencing Market is growing at a CAGR of 21.4% during the forecast period. RNA sequencing, also known as RNA-Seq, is a genomic approach for the detection and quantitative analysis of messenger RNA molecules in a biological sample and is useful for studying cellular responses. RNA sequencing uses the capabilities of high-throughput sequencing methods to provide insight into the transcriptome of a cell. This method is crucial for studying gene expression patterns, understanding cellular processes, identifying biomarkers, and exploring disease mechanisms in various research areas, including genetics, genomics, molecular biology, and medicine.
According to Rare Diseases International, and EURORDIS, rare diseases currently affect at any point in time 3.5% - 5.9% of the worldwide population; 72% are genetic, of which around 70% start in childhood.
Growing demand for precision medicine
RNA sequencing plays a crucial role in precision medicine by enabling comprehensive analysis of an individual's genetic information at the molecular level. Identification of particular genetic variants, patterns of gene expression and genetic markers that impact the susceptibility to disease, its progression, and its response to treatment are rendered easier by it. This comprehensive knowledge makes it possible to implement individualised healthcare interventions, such as targeted therapies and therapies based on a person's genetic profile. Moreover, the capacity of RNA sequencing to interpret complex genetic data has become increasingly essential as precision medicine gains pace. This will encourage the integration of RNA sequencing into clinical care and research, which will fuel market growth for RNA sequencing.
Data analysis challenges
Data analysis complexities pose a restraint in the RNA sequencing market due to the immense data volume and intricacies involved. Analysing RNA sequencing data demands advanced computational infrastructure, specialised algorithms, and bioinformatics expertise to interpret gene expression patterns accurately. Standardising analysis methods across platforms for result consistency is challenging, impacting data reliability. A shortage of skilled analysts and evolving tools further complicate the process. Therefore, it will limit market demand.
Innovation in bioinformatics
Advancements in bioinformatics tools and algorithms enable more sophisticated analysis, interpretation, and visualisation of complex RNA sequencing data. These innovations enhance data accuracy, facilitate the identification of gene expression patterns, splice variants, and non-coding RNAs, and empower researchers to extract meaningful biological insights. Furthermore, improved software solutions streamline data processing, making analysis more accessible to a wider range of users. Continual bioinformatics innovation also drives the development of novel analytical methods, fostering deeper understanding and application of RNA sequencing in diverse research fields, clinical diagnostics, and drug development.
Data security and privacy concerns
The exponential growth in genomic data raises apprehensions about unauthorised access, misuse, and breaches of sensitive genetic information. As RNA sequencing generates extensive personal genetic profiles, ensuring the confidentiality and secure handling of this data becomes paramount. Potential risks include unauthorised data access, identity breaches, and ethical dilemmas related to sharing genomic information. These concerns could erode public trust, resulting in regulatory restrictions on data sharing and utilization.
The COVID-19 pandemic had a significant impact on the RNA sequencing market. Despite the initial hurdles imposed by disrupted supply chains and restricted laboratories, demand for RNA sequencing quickly increased. Researchers accelerated genomic studies to understand the virus, develop vaccines, and identify potential treatments. The industry witnessed an evolution in the direction of automated and remote solutions to lessen operational difficulties. Furthermore, the pandemic underscored the significance of RNA sequencing in the investigation of infectious diseases, cancer, and personalised medicine, hence promoting sustained expansion and variety in the market's applications and solutions.
The Ion Semiconductor Sequencing segment is expected to be the largest during the forecast period
The Ion Semiconductor Sequencing segment is estimated to hold the largest share. Ion semiconductor sequencing is a technique for sequencing DNA that relies on the identification of hydrogen ions generated during DNA polymerization. This method involves detecting changes in pH levels generated as nucleotides are incorporated into a growing DNA strand. Sequencing from Ion Semiconductor is renowned for its quick processing, affordability, and fit for specific sequencing applications. Additionally, it can precisely identify DNA sequences by measuring changes in ion concentrations, making RNA analysis for gene expression research, variant detection, and comprehending biological processes possible.
The Academic and Research Institutes segment is expected to have the highest CAGR during the forecast period
The Academic and Research Institutes segment is anticipated to have lucrative growth during the forecast period. The Academic and Research Institutes comprise educational institutions, universities, and research organisations actively engaged in scientific investigations and genomic studies. These entities play a pivotal role in advancing RNA sequencing technologies by conducting fundamental research, exploring novel applications, and validating sequencing methodologies. They leverage RNA sequencing for diverse purposes, including deciphering gene expression patterns, identifying biomarkers, understanding disease mechanisms, and developing therapeutic interventions. Thus, there is an increasing demand for segment growth.
Asia Pacific commanded the largest market share during the extrapolated period owing to rising adoption of precision medicine, government initiatives supporting genomics research, and a surge in collaborations among academic institutions and biotech firms. Factors like reduced sequencing costs, expanding applications in clinical diagnostics, and the presence of key market players are driving market growth. With growing demand for personalised medicine and advancements in bioinformatics, the Asia-Pacific RNA sequencing market is poised for continuous expansion and innovation, shaping the future of healthcare and biological research in the region.
North America is expected to witness profitable growth over the projection period, owing to the rising acceptance for RNA sequencing techniques. It is characterised by extensive research initiatives, robust funding, and a favourable regulatory landscape. Factors such as increasing investments in genomics research, collaborations between academic institutions and industry players, and the prominence of precision medicine drive market growth. The high demand for RNA sequencing in drug discovery, diagnostics, and personalised medicine, along with advancements in sequencing techniques and data analysis tools, propels the market forward.
Some of the key players in the RNA Sequencing Market include Thermo Fischer Scientific, Illumina, Tecan Genomics Inc., Agilent Technologies Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., GE Healthcare, Bio-Rad Laboratories Inc., Eurofins Scientific, Sigma Aldrich, Admera Health, CD Genomics, Biogazelle, Creative Biogene, LC Sciences, IGA Technology , Lexogen, Otogenetics, Novogene, Yaazh Xenomic and Oxford Nanopore Technologies.
In August 2023, Thermo Fisher Scientific, the world leader in serving science, announced the launch of a new chromosomal microarray designed to improve cytogenetic research lab productivity, efficiency and profitability with an industry-leading two-day turnaround time.
In May 2023, Thermo Fisher Scientific, the world leader in serving science, expanded its manufacturing capacity in St. Louis to support biologic therapies for diseases ranging from cancers to auto immune conditions to rare genetic disorders.
In March 2021, Thermo Fisher Scientific Inc., declared the introduction of the Thermo Scientific Aerosol Sense Sampler, a novel surveillance solution planned to transfer speedy and greatly trustworthy insight into the existence of in-air pathogens, inclusive of SARS-CoV-2. Individual testing will persist in being essential in the COVID-19 pandemic response owing to its ability to allow and apprise clinical diagnoses, patient triage, and treatment decisions.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.